31-Jan-2025
No headlines found.
Business Wire (Tue, 3-Dec 8:25 AM ET)
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
Business Wire (Wed, 13-Nov 4:20 PM ET)
Business Wire (Wed, 13-Nov 4:05 PM ET)
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
Business Wire (Tue, 12-Nov 8:23 AM ET)
Business Wire (Wed, 6-Nov 8:32 AM ET)
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Diamedica Therapeutics trades on the NASDAQ stock market under the symbol DMAC.
As of January 31, 2025, DMAC stock price declined to $5.76 with 53,109 million shares trading.
DMAC has a beta of 1.07, meaning it tends to be more sensitive to market movements. DMAC has a correlation of 0.04 to the broad based SPY ETF.
DMAC has a market cap of $246.20 million. This is considered a Small Cap stock.
In the last 3 years, DMAC traded as high as $6.41 and as low as $1.12.
The top ETF exchange traded funds that DMAC belongs to (by Net Assets): VTI, VXF, IWC, AVSC.
DMAC has outperformed the market in the last year with a price return of +104.3% while the SPY ETF gained +26.1%. DMAC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +31.8% and +0.9%, respectively, while the SPY returned +6.2% and +0.7%, respectively.
DMAC support price is $5.56 and resistance is $6.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DMAC shares will trade within this expected range on the day.